ml210

JKE-1674 is an orally active glutathione peroxidase 4 (GPX4) inhibitor and the active metabolite of ML-210, which is converted to butyronitrile oxide JKE-1777. JKE-1674 kills LOX-IMVI cells in the same manner as ML-210 and is completely rescued by ferroptosis inhibitors.

ML-210 (CID 49766530) is a glutathione peroxidase 4 (GPX4) inhibitor (EC50=30 nM) that is covalent and selective. ML-210 has antitumor activity and induces ferroptosis.

ML210-ansaFc (Compound III-13) is a covalent GPX4 inhibitor featuring a [3]-ferrocenyl group, with an IC50 of 3.4 μM. It effectively induces ferroptosis by elevating ROS levels and promoting lipid peroxidation (LPO) in cancer cells. ML210-ansaFc exhibits anticancer activity and inhibits tumor growth in 3D spheroid models, and it is useful for research on cancer treatment resistance.

Hydroxyl-ML-210 serves as a ligand for target proteins in PROTAC applications (Ligands for Target Protein for PROTACs). It is utilized in synthesis processes.

BML-210 (CAY10433) is a new-type HDAC inhibitor.

Ferroptosis-IN-22 is a selective inhibitor of ferroptosis, which functions by targeting NCOA4 and disrupting its interaction with ferritin, exhibiting an EC50 of 520 nM and a Kd value of 0.78 μM. It effectively inhibits ferroptosis induced by various agents (RSL3, Erastin, ML210, FIN56) but does not inhibit cell necrosis induced by H2O2 or apoptosis induced by STS. Additionally, Ferroptosis-IN-22 significantly ameliorates Concanavalin A-induced acute liver injury and can be used in the study of ferroptosis-related diseases.